DARZALEX® SC development
DARZALEX® SC was developed to reduce patient and provider burden without compromising safety and efficacy
Adapted with permission. © Halozyme, Inc. 2018. All rights reserved. © Janssen Pharmaceuticals, Inc.
Related content
DARZALEX® SC handling and administration
Handling and administration demonstration & information
Overview of the DARZALEX® SC PAVO, COLUMBA and PLEIADES studies
A range of materials, including a practical guide, in-clinic poster and patient materials
DARZALEX® SC MOA
DARZALEX® SC contains recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE® drug delivery technology), an enzyme that disrupts the extracellular matrix to open the subcutaneous space, allowing access to the lymphatic and capillary vessels. The mechanism permits DARZALEX® SC to be absorbed quickly into the systemic circulation.[1][2][3]
DARZALEX® SC dose selection
The DARZALEX® SC 1,800 mg flat dose was selected based on the phase 1b PAVO study[4][5]
DARZALEX® SC provides:[1]
* Compared with DARZALEX® IV.
Quick downloads
SC Checklist beginning of treatment
Includes a first use checklist of Darzalex® SC.
Darzalex® SC Practical Guide
Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more
Glossary
IRR: infusion-related reaction
IV: intravenous
MOA: mode of action
rHuPH20: recombinant human hyaluronidase PH20
SC: subcutaneous
Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Darzalex®, veja aqui